2 FTSE 100 growth stocks to consider buying before it’s too late

Royston Wild looks at two FTSE 100 (INDEXFTSE: UKX) growth greats.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

While Reckitt Benckiser (LSE: RB) has seen its share value snap higher again in recent months — the household goods hulk is currently dealing at five-month highs — I reckon the stock has much, much further to run.

Worth its weight in gold

Reckitt Benckiser took a dive in late 2016 as sales in key territories came under the cosh. Indeed, the Nurofen and Durex maker announced in February that like-for-like revenues had nudged just 3% higher in 2016 as sales growth gradually sank as the year progressed. By comparison, the top-line rose 6% in 2015 on an underlying basis.

More recently Reckitt Benckiser has been whacked by difficult trading conditions in Korea and Russia, for example. But this has not caused group-wide sales to drop off a cliff, particularly as its products continue to fly off the shelves in highly-promising developing markets — the firm saw aggregate like-for-like sales in these territories rise 8% last year.

And the City believes Reckitt Benckiser has what it takes to keep growing the bottom line. The company is currently slated to enjoy a 10% earnings bounce in 2017, and an extra 8% rise is pencilled in for 2018.

Sure, these figures result in slightly-heady P/E ratios of 21.9 times and 20.3 times respectively, operating above the FTSE 100 prospective mean of 15 times.

But the scale of Reckitt Benckiser’s stable of market-leading products — goods that boast brilliant pricing power and thus enable sales to keep rising regardless of broader pressure on shoppers’ pursetrings — is worth its weight in gold.

And Reckitt Benckiser’s broad geographic footprint, boosted by its healthy appetite for acquisitions like baby formula maker Mead Johnson, which it bought up in February, also offers up plenty of growth potential.

Medical star

Like Reckitt Benckiser, artificial joint-and-limb leviathan Smith & Nephew (LSE: SN) has also seen its share price rocket since the dying embers of 2016.

Smith & Nephew has not had the best of it in recent times as revenues sunk in many of its territories, and particularly in China due to distributor de-stocking earlier in the year, and in the Gulf where depressed oil values affected healthcare spend.

However, with emerging market activity bouncing back during the latter part of the year, and economic conditions improving in Smith & Nephew’s largest market of the US, I reckon revenues should pick up again from the current period.

The City shares this optimistic view, and expects the London firm to get moving back in the right direction from 2017 with a fractional earnings uptick. And a 10% advance is anticipated for next year.

These forecasts yield P/E ratios of 18.2 times and 16.6 times. And I believe this is a great time to get in on the bodybuilder as global spending for its high-tech products — helped by shrewd investment in hot growth areas like sports medicine — looks set to explode in the years ahead.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any shares mentioned. The Motley Fool UK has recommended Reckitt Benckiser. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »